Aetna Oral Lesion Identification Coverage Update

Experimental and Investigational

The following procedures are considered experimental and investigational because the effectiveness has not been established:

Experimental/Investigational List: Epstein-Barr virus (EBV) testing for screening for oral squamous cell carcinoma; oral human papillomavirus (HPV) testing (e.g., OraRisk HPV Salivary DNA Test) for all indications; salivary biomarkers (DUSP100, IL-1B, IL-8, MMP-9, microRNA, mRNA, s100P, TNF-alpha) for screening and detection of oral squamous cell carcinomas; salivary hypermethylated DNA biomarkers; salivary metabolite biomarkers for screening of OSCC and oral epithelial dysplasia from persistent suspicious lesions; tumor-derived exosomal (TEX) biomarkers from liquid biopsy; chemiluminescence; confocal laser endomicroscopy; diffuse reflectance spectroscopy; fluorescence spectroscopy; MOP genetic testing; narrow band imaging; optical filter for autofluorescence (GOCCLES); optical fluorescence imaging (e.g., 5-ALA induced PpIX fluorescence, autofluorescence); oral lesion identification systems (e.g., Dentlight Oral Exam Light Kit, Microlux DL, Orascoptic DK, Sapphire Plus, TRIMIRA Identafi 3000, ViziLite-Blue, VELscope); Straticyte; wide-field and high-resolution in-vivo imaging; and salivary metabolite biomarkers.

Listed verbatim as experimental/investigational in policy

Coverage considerations and clinical role

Coverage and clinical use considerations based on evidence presented

Adjunctive devices are supplemental: Adjunctive imaging devices (chemiluminescence, autofluorescence, tissue reflectance, spectroscopy and related optical aids) are intended as aids to a comprehensive oral examination (COE) and are not replacements for clinical examination and scalpel biopsy/histopathology.

Supported by multiple systematic reviews and guidelines

Utility limited or uncertain: Systematic reviews and guideline evaluations report inconsistent results, high risk of bias in many studies, and insufficient evidence that adjunctive devices improve diagnostic accuracy or reduce oral cancer mortality in screening settings; methods cannot substitute for biopsy.

Cochrane review, USPSTF, ADA and recent systematic reviews cited

Potential adjunctive role in selected settings: In selected high-risk populations or specialist settings some devices (for example, VELscope) may increase sensitivity or assist margin delineation, but specificity is variable and findings require interpretation by experienced clinicians with confirmatory biopsy when indicated.

Examples: margin assessment, high-risk cohorts; evidence limited and heterogeneous

Adjunctive imaging — evidence summary

Findings from systematic reviews and studies summarized in this section:

Adjunctive non-invasive imaging performance and limitations: Autofluorescence devices (eg, VELscope) and fluorescent probes (eg, 5-ALA) demonstrate highly variable sensitivity and specificity across studies (VELscope sensitivity reported ~33%–100% and specificity ~12%–88.6%; 5-ALA sensitivity commonly high 90%–100% with variable specificity). Some techniques such as fluorescence spectroscopy (FS), diffuse reflectance spectroscopy (DRS), and 5-ALA induced PpIX show higher reported accuracy for differentiating dysplastic OPMDs from non-dysplastic lesions in pooled analyses, but studies are heterogeneous, often small, lack standardized protocols, and cannot replace histopathology. Standardization of protocols, larger prospective validation studies, and assessment of clinical and economic impact are needed before these methods can be considered diagnostic substitutes for biopsy.

Summary of Lima et al, Dos Santos et al, Mendonca et al, GOCCLES and others; highlights performance ranges and need for validation

The policy lists multiple adjunctive technologies and biomarker assays that are considered experimental and investigational because their clinical effectiveness for early detection or diagnosis of oral cancer has not been established. Examples explicitly named include EBV antibody testing, oral HPV testing (e.g., OraRisk), numerous salivary biomarkers and hypermethylated DNA markers, tumor-derived exosomal biomarkers, and a range of device- and imaging-based aids (eg, chemiluminescence, confocal laser endomicroscopy, diffuse reflectance and fluorescence spectroscopy, narrow band imaging, optical fluorescence imaging including 5‑ALA induced PpIX and autofluorescence, GOCCLES, and commercial oral lesion identification systems such as ViziLite-Blue and VELscope). These listed technologies are therefore not supported for coverage under this policy.

Systematic reviews and guideline statements indicate that no evaluated imaging-based adjunct can substitute for a tissue diagnosis by biopsy and histopathology. A 2022 systematic review found inconsistent results across studies, high risk of bias, and concluded that none of the evaluated imaging methods could replace oral biopsy. Earlier reviews and guidance similarly note insufficient evidence to support routine population screening with adjunctive devices and recommend that these tools be used only as supplements to a comprehensive clinical oral examination (COE).

Screening for oral HPV infection is not recommended by major medical and dental organizations, and no FDA‑approved screening test for oral HPV infection currently exists. Although detection of oral HPV is an area of active research, available guidance does not support routine screening of asymptomatic populations for oral HPV.

Adjunctive tests such as vital staining, brush cytology and light‑based detection have not demonstrated sufficient quality of evidence to replace scalpel biopsy. Meta-analyses show variable accuracy across methods and overall study quality is poor; therefore, these adjunctive modalities cannot supplant histologic assessment as the definitive diagnostic standard.

Optical fluorescence, cytology and biomarker assays are discussed in the literature as potential adjuncts, but current evidence does not support their use as replacements for surgical biopsy and histopathological evaluation. Even when adjuncts provide immediate or less invasive results, confirmatory biopsy remains necessary to establish diagnosis and guide management.

Many salivary techniques and candidate biomarkers lack clinical validation, standardization, and robust prospective evidence. Studies frequently used research‑use‑only ELISA reagents, had heterogeneous methods of saliva collection and assay, small sample sizes, and variable reporting of diagnostic metrics. These limitations mean numerous salivary assays and other biomarkers remain unvalidated for routine clinical use.

Across imaging and probe-based adjuncts, authors consistently conclude that these techniques are unable to replace histopathological examination for definitive diagnosis. While some modalities (eg, certain fluorescent probes or spectroscopic methods) may show promising sensitivity or specificity in select studies, methodological heterogeneity, small cohorts, and lack of prospective outcome data preclude substituting imaging-based findings for biopsy and histology.

Adjunctive imaging devices should be considered aids to, not substitutes for, a comprehensive oral examination and targeted tissue biopsy. Guideline and systematic review conclusions emphasize that clinical decision-making should rely on COE and confirmatory histopathology; using adjunctive imaging as a standalone substitute for biopsy is unsupported by the evidence.

Computer‑aided cytology, liquid‑based cytology, and other adjunctive technologies have not demonstrated sufficient, consistent evidence to be recommended as replacements for scalpel biopsy. Systematic reviews identify oral cytology as having potential diagnostic value but do not endorse any adjunctive technique as a definitive alternative to histopathology.

The evidence does not support use of autofluorescence devices or fluorescent probes as standalone replacements for biopsy and histopathology to establish malignancy. Systematic reviews report variable performance metrics, lack of standardized fluorescence measurement thresholds, and frequent methodological limitations that preclude recommending these modalities as definitive diagnostic tests.

Provider Responsibilities, Documentation, and Authorization

Billing Rule

Coding and coverage identification

Coding and coverage identification — Codes associated with listed adjunctive tests and unlisted oral procedures are identified in this policy. Providers should bill the applicable CPT/HCPCS/ICD-10 codes noted in the policy; services for technologies or indications described as experimental/investigational or not supported by the policy may be denied.

Relevant CPT/HCPCS examples: 40899, 41599, 41899 (unlisted oral procedures); 82397 (chemiluminescent assay); 87623-87625 (HPV NAATs); HCPCS D0431 (adjunctive pre-diagnostic test); G0476.
ICD-10 examples noted as not covered for screening indications: Z12.81; C00.0-C10.9; D00.00-D00.08; D37.01-D37.09; K00.0-K14.9.

Denial Risk

Denial risk for experimental/investigational technologies

Denial risk for experimental/investigational technologies — Use of procedures or assays described as experimental, investigational, pre-market, research-use-only, or lacking sufficient clinical validation may result in claim denial. Confirm plan-specific coverage before ordering or billing.

Examples include Straticyte™ (pre-market), many salivary biomarker assays using RUO ELISA kits, novel microRNA or hypermethylated DNA panels, and certain optical/fluorescent probes without demonstrated clinical utility.
Providers should verify medical necessity and local plan criteria; absence of stated coverage in the Clinical Policy Bulletin does not guarantee payment.

Note

Clinical validation required

Clinical validation required — Many salivary assays, biomarker tests, and novel adjunctive technologies lack standardized collection, analytic validation, and robust prospective clinical validation. Such tests should not be used as replacements for histopathology and may be considered investigational until validated.

Salivary cytokine and hypermethylated DNA studies show heterogeneity and use RUO reagents; standardization of saliva collection and assay platforms is needed.
Stratified, multi-center prospective data demonstrating diagnostic accuracy and clinical utility are required before routine clinical adoption.

Prior Authorization

Plan-level prior authorization

Plan-level prior authorization — This Clinical Policy Bulletin provides guidance but does not itself establish prior authorization. Providers must follow plan-specific prior authorization requirements and check benefit documents or prior authorization portals before performing adjunctive tests or novel assays.

Policy bulletin content does not replace plan administrative rules; contact the member's plan for authorization requirements.
Failure to obtain required prior authorization may lead to claim denial or member liability.

Prior Authorization

Prior authorization

Prior authorization — No universal prior authorization is specified in this section; however, some tests or procedures (particularly novel assays, unlisted procedures, or experimental technologies) may require prior authorization under the member’s plan.

Verify prior authorization requirements for unlisted procedure codes (e.g., 40899, 41599, 41899) and for biomarker/diagnostic codes before scheduling.
Document clinical rationale and supporting records when seeking authorization.

Denial Risk

Insufficient evidence that routine screening reduces mortality

Insufficient evidence that routine screening reduces mortality — Systematic reviews and USPSTF guidance indicate insufficient evidence to recommend routine population screening for oral cancer using adjunctive devices or tests; routine screening outside established guidelines risks unsupported care.

Professional bodies do not recommend routine oral HPV screening; no FDA-approved oral HPV screening tests exist.
Routine use of adjunctive devices without appropriate clinical indications may not improve outcomes and can risk denial.

Documentation Required

Adjunctive tests are not definitive

Adjunctive tests are not definitive — Adjunctive devices and tests (autofluorescence, chemiluminescence, toluidine blue, brush cytology, optical filters, salivary biomarkers) are aids to clinical assessment and are not replacements for scalpel biopsy and histopathologic diagnosis.

None of the evaluated adjunctive methods can substitute for surgical biopsy and histological assessment; oral cytology shows promise but is not definitive.
Adjunctive findings should be used to guide clinical judgment and decisions about referral and biopsy.

Note

Adjunctive tools are not a substitute; devices are aids

Adjunctive tools are not a substitute; adjunctive devices are aids — Use adjunctive devices only in conjunction with a comprehensive clinical oral examination (COE). They may assist in lesion identification or targeting biopsy sites but do not replace COE, histopathology, or clinical judgment.

When using devices like VELscope, ViziLite, or GOCCLES, perform and document a full COE and use device findings to inform, not replace, biopsy decisions.
Positive adjunctive findings should prompt referral to experienced providers or biopsy when clinically indicated.

Documentation Required

Imaging adjuncts do not replace biopsy

Imaging adjuncts do not replace biopsy — Non-invasive imaging modalities (autofluorescence, fluorescent probes, optical filters) can aid detection and surveillance but cannot replace histopathologic confirmation.

Document that imaging was used to assist selection of biopsy site or surveillance; ensure biopsy and histology remain the diagnostic standard.
Imaging may improve lesion conspicuity or help target biopsies in OPMD but is not diagnostic alone.

Documentation Required

Clinical examination findings and rationale

Clinical examination findings and rationale — When adjunctive tests are used, document the comprehensive oral examination findings, risk factors, and the clinical rationale for selecting biopsy sites or surveillance rather than immediate biopsy.

Document duration of lesion (any abnormality >2 weeks should be reevaluated and considered for biopsy), size, appearance, anatomic location, patient risk factors (tobacco, alcohol, immunosuppression), and device findings.
If choosing surveillance instead of biopsy, record the rationale, follow-up interval, and criteria for escalation or biopsy.

Documentation Required

Any abnormality in the oral cavity that persists >2 weeks

Any abnormality in the oral cavity that persists >2 weeks — Lesions lasting longer than 2 weeks should be reevaluated and considered for biopsy; adjunctive test results do not obviate this recommendation.

Record follow-up plans and outcomes; persistent lesions, VELscope-positive areas that do not resolve within 2 weeks, or lesions with concerning features warrant further assessment and usually biopsy.

Documentation Required

Assay and collection documentation

Assay and collection documentation — For salivary or other biomarker testing, document the assay platform, specimen collection method, reagent status (e.g., Research Use Only), and analytic validation status in the medical record.

Standardize and record saliva collection protocols, storage conditions, and assay kit lot/brand when available.
Note if assays use RUO reagents or lack clinical regulatory approval; include these details when submitting claims or prior authorization requests.

Documentation Required

Documentation when using adjunctive imaging

Documentation when using adjunctive imaging — When autofluorescence, chemiluminescence, toluidine blue, or other imaging adjuncts are used, document the COE findings, device observations, targeted biopsy site selection rationale, and subsequent histopathology results.

Include device type, settings or protocol used (if available), and whether software quantification was applied.
Record referral actions, biopsy dates, and histologic outcomes to support medical necessity and appropriate follow-up.

Definitions and Device Descriptions

inv-46: ViziLite-Blue — chemiluminescent light oral exam kit cleared by FDA (definition/key features)

DeviceViziLite-Blue oral examination kit (chemiluminescent light oral exam kit)

Regulatory statusCleared by the U.S. Food and Drug Administration via 510(k) (FDA clearance as adjunct to visual oral exam)

ComponentsChemiluminescent light source (ViziLite) plus blue phenothiazine dye to mark lesions

Intended useAdjunct to conventional head and neck examination for patients at increased risk for oral cancer; aids identification and marking of mucosal abnormalities

Clinical roleDesigned as an adjunctive identification/marking system to improve lesion visualization, not a replacement for biopsy and histology

inv-47: VELscope / fluorescence visualization (FV) — hand-held autofluorescence device description

DeviceVELscope (hand-held autofluorescence device)

Excitation lightBlue/violet excitation light approximately 400–460 nm (visible light ~430 nm used to excite tissue fluorescence)

FunctionVisualizes differences in tissue autofluorescence to aid detection of mucosal abnormalities and assist surgical margin delineation

Regulatory statusReceived 510(k) market clearance; deemed substantially equivalent to ViziLite

inv-48: Chemiluminescence (ViziLite) — light-based adjunctive screening technique definition and evidence note

DefinitionLight-based adjunctive screening technique using chemiluminescence to enhance visualization of oral mucosal abnormalities

Diagnostic accuracy noteMeta-analyses report chemiluminescence sensitivity comparable to or worse than toluidine blue and clinical exam; no added benefit over standard screening in some analyses

Evidence limitationsExisting reviews include heterogeneous studies (e.g., 16 studies in one meta-analysis) and recommend standardized, controlled studies to determine clinical utility

inv-49: OraRisk HPV — salivary diagnostic test detecting oral HPV DNA; evidence insufficient for screening

TestOraRisk HPV (salivary diagnostic test)

MethodPatient performs saline mouth rinse and expectorates sample sent to laboratory for HPV DNA detection

Evidence statementCurrent evidence is insufficient to establish clinical value of OraRisk for detecting oral cancer; saliva HPV detection studies show inconsistent results

inv-50: Adjunctive tests — general definition listing toluidine blue, chemiluminescent devices, autofluorescence, brush cytology, biomarkers

DefinitionNon-surgical diagnostic aids used alongside visual examination (eg, toluidine blue, chemiluminescent devices, autofluorescence, brush cytology, biomarkers)

Clinical limitationAdjunctive tests cannot replace scalpel biopsy and histologic assessment; they are aids and not standalone diagnostic replacements

ExamplesToluidine blue staining, chemiluminescent lighting devices (ViziLite), autofluorescence devices (VELscope), brush cytology, salivary biomarkers

inv-51: MOP genetic test — commercial genetic test assessing cell abnormalities, HPV, and DNA damage for risk stratification

TestMOP genetic test (commercially described)

Components assessedCell abnormalities, HPV status, and DNA damage

Intended purposeReportedly used to stratify oral cancer risk and recommend increased monitoring frequency

inv-52: HPV testing in oral cavity — molecular and IHC assays used to detect HPV in oral/oropharyngeal tumors; correlation notes

AssaysMolecular and immunohistochemical assays used in oral/oropharyngeal tumors (eg, p16 IHC, PCR for HPV16/18 DNA, in-situ hybridization)

CorrelationCorrelation among different assays may be poor; HPV-driven disease appears uncommon in squamous cell carcinoma of the oral cavity (SCCOC)

Clinical implicationAssay results and prognostic implications vary by technique; comprehensive interpretation and validation needed

inv-53: miRNA panels — circulating or tissue microRNA profiles proposed as biomarkers to differentiate OSCC/high-risk lesions

Biomarker classmiRNA panels (circulating or tissue microRNA profiles)

Diagnostic performanceMeta-analyses report pooled sensitivities and specificities with AUCs (eg, pooled AUC ~0.832), suggesting potential but requiring larger validation studies

Current statusPromising diagnostic value for OSCC detection but needs rigorous large-scale validation before routine clinical use

inv-54: Optical autofluorescence (AF/FV) — noninvasive imaging adjunct to COE with higher sensitivity but limitations

ModalityOptical autofluorescence / autofluorescence imaging (AF/FV)

Performance characteristicsHigher sensitivity than clinical exam in many studies but lower specificity; reported sensitivity and specificity vary widely across studies

Clinical roleNoninvasive adjunct to comprehensive oral exam to increase lesion detection and aid visualization; not sufficiently accurate to replace biopsy

Devices/examplesVELscope, GOCCLES (autofluorescence filters)

inv-55: Salivary biomarkers (salivaomics) — panels of DNA, RNA, protein and other molecules in saliva under investigation

DefinitionSalivary biomarkers (salivaomics): panels of DNA, RNA, protein, cytokines, metabolites and other molecules detectable in saliva

Discovery statusOver 100 candidate salivary biomarkers have been identified (DNA, RNA, mRNA, proteins, cytokines) but none validated for routine clinical use

Promise and limitationSaliva is noninvasive and in direct contact with lesions, making it promising for early detection, but standardization, assay validation, and large-scale studies are needed

inv-56: Salivary biomarkers — molecular signatures in saliva indicating premalignant or malignant processes

DefinitionMolecular signatures in saliva (DNA, RNA, proteins, cytokines, metabolites) that may indicate premalignant or malignant oral processes

Clinical statusNumerous candidates identified but further validation required before clinical adoption

ImplicationMay support noninvasive surveillance or adjunct testing once validated and standardized

inv-57: Confocal laser endomicroscopy (CLE) — high-resolution imaging technique with reported high pooled sensitivity and specificity

TechniqueConfocal laser endomicroscopy (CLE)

Imaging capabilityProvides high-resolution, in vivo imaging of mucosal tissues potentially enabling real-time assessment

Reported diagnostic accuracySystematic review/meta-analysis reported pooled sensitivity ~95% and specificity ~93% for diagnosing OSCC in included studies

inv-58: Narrow band imaging (NBI) — endoscopic imaging enhancing mucosal vasculature visualization with promising accuracy

TechniqueNarrow band imaging (NBI)

FunctionEndoscopic imaging that enhances visualization of mucosal vasculature to aid detection of dysplasia and malignancy

EvidenceMeta-analysis reported pooled sensitivity ~91.5% and specificity ~75.7% in selected studies; promising tool though higher-powered prospective studies are needed

inv-59: 5-ALA induced PPIX — fluorescent probe technique to induce protoporphyrin IX fluorescence for detection of dysplasia/malignancy

Technique5-ALA induced protoporphyrin IX (PPIX) fluorescence

MethodAdministration of 5-aminolevulinic acid induces PPIX fluorescence in dysplastic/malignant tissue which can be visualized with fluorescent probes

PerformanceSystematic reviews report high sensitivity (eg, 90–100%) and variable specificity (eg, 51.3–96%) across studies; may aid detection but does not replace histopathology

inv-60: Autofluorescence imaging (AFI) — device-based tissue fluorescence visualization (VELscope, GOCCLES) used as adjunct to exam

DefinitionAutofluorescence imaging (AFI): device-based visualization of tissue fluorescence (eg, VELscope, GOCCLES) used as adjunct to conventional oral exam

Clinical findingsStudies show increased lesion detection and higher sensitivity than white-light exam in many series, but specificity is variable and unable to replace biopsy

ExamplesVELscope, GOCCLES optical filter; used to highlight areas of abnormal fluorescence for targeted biopsy or monitoring

40899	Unlisted procedure, vestibule of mouth
41599	Unlisted procedure, tongue, floor of mouth
41899	Unlisted procedure, dentoalveolar structures
82397	Chemiluminescent assay
87623	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44)
87624	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)
87625	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed

A69.0	Chancroid (example code listed in ICD-10 not covered list context)
K00.0-K14.9	Disease of oral cavity, salivary glands, and jaws
C00.0-C10.9	Malignant neoplasm of lip and oral cavity
D00.00-D00.08	Carcinoma in situ of lip, oral cavity, and pharynx
D37.01-D37.02, D37.04-D37.09	Neoplasm of uncertain behavior of lip, oral cavity, and pharynx
Z12.81	Encounter for screening for malignant neoplasms of oral cavity

OpenPayer

Oral Screening and Lesion Identification Systems

Coverage Criteria and Evidence Summary

Coding and Billing

Provider Responsibilities, Documentation, and Authorization

Background and Context

Definitions and Device Descriptions

Policy Revision History

D0431	Adjunctive pre-diagnostic test that aids in detection of mucosal abnormalities including premalignant and malignant lesions, not to include cytology or biopsy procedures
G0476	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types for cervical cancer screening, must be performed in addition to pap test